Redeye provides an update following Optomed’s FDA clearance for Aurora AEYE and the company’s Q1 report. The report fairly aligned with our expectations; however, slightly lower sales than expected. Moreover, we argue that the FDA clearance is a major milestone for the company and that upcoming US subscriptions could generate a significant part of future sales. We make some changes to our US sales approach assumptions, rendering an updated fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/